Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERICA: ESK981 in Metastatic RCC
NCT03562507Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CEP-11981 in renal cell carcinoma (RCC), sponsored by University of Michigan Rogel Cancer Center. Started Apr 2019; status: terminated.
02
Drugs
CEP-11981
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03562507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562507.